These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 14513166)

  • 21. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ptosis as a remote effect of therapeutic botulinum toxin B injection.
    Racette BA; Lopate G; Good L; Sagitto S; Perlmutter JS
    Neurology; 2002 Nov; 59(9):1445-7. PubMed ID: 12427903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin A--injection for cervical dystonia.
    Bhaumik S; Behari M
    J Assoc Physicians India; 1999 Mar; 47(3):267-70. PubMed ID: 10999117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
    Rosales RL; Ng AR; Santos MM; Fernandez HH
    Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox.
    Dutton JJ; White JJ; Richard MJ
    Ophthalmic Plast Reconstr Surg; 2006; 22(3):173-7. PubMed ID: 16714924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.
    Brashear A; Watts MW; Marchetti A; Magar R; Lau H; Wang L
    Clin Ther; 2000 Dec; 22(12):1516-24. PubMed ID: 11192142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Indications and management of botulinum toxin].
    Singer C
    Rev Neurol; 1999 Jul 16-31; 29(2):157-62. PubMed ID: 10528331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.
    Adler CH; Factor SA; Brin M; Sethi KD
    Mov Disord; 2002 Jan; 17(1):158-61. PubMed ID: 11835455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Botulinum A toxin in the treatment of focal dystonias].
    Domzał TM
    Neurol Neurochir Pol; 1998; 32 Suppl 1():35-44. PubMed ID: 9608551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs of treating dystonias and hemifacial spasm with botulinum toxin A.
    Dodel RC; Kirchner A; Koehne-Volland R; Künig G; Ceballos-Baumann A; Naumann M; Brashear A; Richter HP; Szucs TD; Oertel WH
    Pharmacoeconomics; 1997 Dec; 12(6):695-706. PubMed ID: 10175981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
    Nüssgens Z; Roggenkämper P
    Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
    Greene PE; Fahn S
    Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin in Meige's syndrome: A video-based case series.
    Pandey S; Sharma S
    Neurol India; 2018; 66(1):71-76. PubMed ID: 29322963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term remission of idiopathic cervical dystonia after treatment with botulinum toxin.
    Giladi N; Meer J; Kidan H; Honigman S
    Eur Neurol; 2000; 44(3):144-6. PubMed ID: 11053961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia.
    Ansved T; Odergren T; Borg K
    Neurology; 1997 May; 48(5):1440-2. PubMed ID: 9153487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin type B: a new injectable treatment for cervical dystonia.
    Brashear A
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2191-9. PubMed ID: 11772315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin A for patients with orofacial dystonia: prospective, observational, single-centre study.
    Ruiz-de-León-Hernández G; Díaz-Sánchez RM; Torres-Lagares D; Hernández-Pacheco E; González-Martín M; Serrera-Figallo MA
    Int J Oral Maxillofac Surg; 2018 Mar; 47(3):386-391. PubMed ID: 29208327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.
    Pullman SL; Greene P; Fahn S; Pedersen SF
    Arch Neurol; 1996 Jul; 53(7):617-24. PubMed ID: 8929169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.